BioCentury | Jan 26, 2015
Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes Analyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 1/23 cls Arrowhead Research Corp. (NASDAQ:ARWR) Deutsche Bank Alethia Young Downgrade Hold (from buy) -6% $6.43 Young also lowered her...
BioCentury | Apr 28, 2014
Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 4/25 cls BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) Brinson Patrick Christopher James New Market outperform -4% $8.01 James initiated coverage with a $15 target. He expects...
BioCentury | Apr 21, 2014
Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 4/17 cls Akebia Therapeutics Inc. (NASDAQ:AKBA) UBS Matthew Roden New Buy 55% $26.09 Roden initiated coverage with a $28 target on the belief that...
BC Week In Review | Feb 17, 2014
Company News

Fluidigm, DVS Sciences deal

Microfluidics company Fluidigm completed its acquisition of DVS Sciences, which develops and markets single-cell protein analysis systems, for about $207.5 million in a cash and stock deal (see BioCentury, Feb. 3). Fluidigm Corp. (NASDAQ:FLDM), South...
BioCentury | Feb 10, 2014
Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 2/7 cls Fluidigm Corp. (NASDAQ:FLDM) Cowen Doug Schenkel Downgrade Market perform (from outperform) -4% $43.11 Schenkel raised his target to $45 from $42, saying...
BC Week In Review | Feb 3, 2014
Company News

Fluidigm, DVS Sciences deal

Microfluidics company Fluidigm is acquiring DVS Sciences for about $207.5 million in a cash and stock deal. DVS develops and markets single-cell protein analysis systems, including its CyTOF2 mass cytometer. Fluidigm said DVS will complement...
BioCentury | Feb 3, 2014
Finance

Quick payday on single cell sale

A quick turnaround from first financing to takeout netted investors in DVS Sciences Inc. an impressive return in a short time. On Jan. 29, Fluidigm Corp. (NASDAQ:FLDM) announced plans to acquire fellow microfluidics company DVS...
BC Extra | Jan 30, 2014
Company News

Fluidigm to acquire DVS Sciences

Microfluidics company Fluidigm Corp. (NASDAQ:FLDM) is acquiring DVS Sciences Inc. (Sunnyvale, Calif.) for about $207.5 million in a cash and stock deal. DVS develops and markets single-cell protein analysis systems, including its CyTOF2 mass cytometer....
BC Innovations | Sep 13, 2012
Distillery Techniques

Technology: Drug platforms

Approach Summary Licensing status Publication and contact information Drug platforms High throughput flow cytometry for small molecule screening High throughput, multiplexed flow cytometry could provide a way to rapidly screen small molecules in immune cells....
BioCentury | Aug 27, 2012
Tools & Techniques

Network profiling

Pfizer Inc. believes new partner Nodality Inc. 's Single Cell Network Profiling technology will provide early insight into a compound's clinical profile, which could help reduce attrition rates, accelerate development and improve patient selection. The...
Items per page:
1 - 10 of 15
BioCentury | Jan 26, 2015
Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes Analyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 1/23 cls Arrowhead Research Corp. (NASDAQ:ARWR) Deutsche Bank Alethia Young Downgrade Hold (from buy) -6% $6.43 Young also lowered her...
BioCentury | Apr 28, 2014
Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 4/25 cls BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) Brinson Patrick Christopher James New Market outperform -4% $8.01 James initiated coverage with a $15 target. He expects...
BioCentury | Apr 21, 2014
Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 4/17 cls Akebia Therapeutics Inc. (NASDAQ:AKBA) UBS Matthew Roden New Buy 55% $26.09 Roden initiated coverage with a $28 target on the belief that...
BC Week In Review | Feb 17, 2014
Company News

Fluidigm, DVS Sciences deal

Microfluidics company Fluidigm completed its acquisition of DVS Sciences, which develops and markets single-cell protein analysis systems, for about $207.5 million in a cash and stock deal (see BioCentury, Feb. 3). Fluidigm Corp. (NASDAQ:FLDM), South...
BioCentury | Feb 10, 2014
Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 2/7 cls Fluidigm Corp. (NASDAQ:FLDM) Cowen Doug Schenkel Downgrade Market perform (from outperform) -4% $43.11 Schenkel raised his target to $45 from $42, saying...
BC Week In Review | Feb 3, 2014
Company News

Fluidigm, DVS Sciences deal

Microfluidics company Fluidigm is acquiring DVS Sciences for about $207.5 million in a cash and stock deal. DVS develops and markets single-cell protein analysis systems, including its CyTOF2 mass cytometer. Fluidigm said DVS will complement...
BioCentury | Feb 3, 2014
Finance

Quick payday on single cell sale

A quick turnaround from first financing to takeout netted investors in DVS Sciences Inc. an impressive return in a short time. On Jan. 29, Fluidigm Corp. (NASDAQ:FLDM) announced plans to acquire fellow microfluidics company DVS...
BC Extra | Jan 30, 2014
Company News

Fluidigm to acquire DVS Sciences

Microfluidics company Fluidigm Corp. (NASDAQ:FLDM) is acquiring DVS Sciences Inc. (Sunnyvale, Calif.) for about $207.5 million in a cash and stock deal. DVS develops and markets single-cell protein analysis systems, including its CyTOF2 mass cytometer....
BC Innovations | Sep 13, 2012
Distillery Techniques

Technology: Drug platforms

Approach Summary Licensing status Publication and contact information Drug platforms High throughput flow cytometry for small molecule screening High throughput, multiplexed flow cytometry could provide a way to rapidly screen small molecules in immune cells....
BioCentury | Aug 27, 2012
Tools & Techniques

Network profiling

Pfizer Inc. believes new partner Nodality Inc. 's Single Cell Network Profiling technology will provide early insight into a compound's clinical profile, which could help reduce attrition rates, accelerate development and improve patient selection. The...
Items per page:
1 - 10 of 15